News

Community-based organizations in Canada addressing hepatitis C, the human immunodeficiency virus (HIV), and other sexually transmitted and blood-borne infections (STBBIs) will receive more than…

The U.S. Food and Drug Administration (FDA) will review CymaBay Therapeutics’ application for seladelpar, an oral investigational treatment for adults with…

In infants with suspected cholestasis, targeted single-gene testing for those with symptoms that indicate a particular, associated disease and broader gene panel testing for…

Weekly injections of tirzepatide, an approved obesity and diabetes treatment, showed promise in people with nonalcoholic steatohepatitis (NASH) — now known as metabolic dysfunction-associated steatohepatitis…

Researchers have identified two new mutations in JAG1, a gene linked to Alagille syndrome, that each resulted in a unique clinical profile for two…

A combination of the antiviral medications ribavirin and sofosbuvir efficiently cleared the hepatitis E virus (HEV) from two chronically infected patients despite the emergence of…

Seladelpar, an experimental oral therapy by CymaBay Therapeutics, significantly lowered blood levels of an itch-associated molecule called interleukin-31 (IL-31) in people with…

In a wide-ranging analysis of thousands of different proteins from liver samples from transplant patients, a team of scientists in Spain discovered potential links to…

Denifanstat, Sagimet Biosciences’ experimental therapy, outperformed a placebo at resolving nonalcoholic steatohepatitis (NASH) — a severe form of fatty liver disease —…

Rare Liver Diseases Month, observed every February, seeks to call attention to the more than 100 rare liver disorders that affect a significant portion…